{"id":15368,"date":"2025-04-24T05:30:00","date_gmt":"2025-04-24T05:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/delarsrapport-januari-mars-2025\/"},"modified":"2025-04-24T05:30:00","modified_gmt":"2025-04-24T05:30:00","slug":"delarsrapport-januari-mars-2025","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/","title":{"rendered":"Del\u00e5rsrapport januari-mars 2025"},"content":{"rendered":"<div class=\"mfn-body\">\n<p><strong class=\"mfn-heading-2\">F\u00f6rsta kvartalet 2025 (Jan &#8211; Mar)<\/strong><br \/>\u2022 Nettooms\u00e4ttningen \u00f6kade till 218,6 MSEK (186,0), motsvarande en tillv\u00e4xt om 18 procent i SEK och 16 procent i lokala valutor. Organisk tillv\u00e4xt var 14 procent i lokala valutor.<br \/>\u2022 Aff\u00e4rsomr\u00e5de Thorax och Abdominal visade p\u00e5 f\u00f6rs\u00e4ljningstillv\u00e4xt i lokala valutor; Thorax 16 procent och Abdominal 28 procent. Services visade p\u00e5 negativ tillv\u00e4xt med -6 procent.<br \/>\u2022 Total bruttomarginal uppgick till 73 procent (73). Bruttomarginal f\u00f6r aff\u00e4rsomr\u00e5dena uppgick till: Thorax 82 procent (81), Abdominal 63 procent (68) och Services 38 procent (36).<br \/>\u2022 R\u00f6relseresultatet (EBIT) \u00f6kade till 26,6 MSEK (19,0). Justerad EBIT \u00f6kade med 50 procent till 29,8 MSEK (19,9).<br \/>\u2022 R\u00f6relseresultat f\u00f6re avskrivningar (EBITDA) \u00f6kade till 43,0 MSEK (36,0) motsvarande en EBITDA-marginal om 20 procent (19). Justerad EBITDA \u00f6kade till 46,2 MSEK (36,9), motsvarande en justerad EBITDA-marginal om 21 procent (20).<br \/>\u2022 Nettoresultatet uppgick till -12,4 MSEK (22,8), p\u00e5verkat av valutaeffekter i likvida medel om -22,5 (8,3). Resultat per aktie uppgick till -0,39 SEK (0,72).<br \/>\u2022 Kassafl\u00f6de fr\u00e5n den l\u00f6pande verksamheten uppgick till -15,3 MSEK (1,6). Kvartalet p\u00e5verkades av \u00f6kad r\u00f6relsekapitalbindning fr\u00e5n \u00f6kad f\u00f6rs\u00e4ljning samt \u00e5rlig utbetalning av personalrelaterade skulder. Totalt kassafl\u00f6de uppgick till -77,2 MSEK (-43,3), prim\u00e4rt p\u00e5verkat av investeringar i FoU-projekt om -40,1 MSEK.<\/p>\n<p><strong class=\"mfn-heading-2\">V\u00e4sentliga h\u00e4ndelser under kvartalet<\/strong><br \/>\u2022 Snabbt FDA-godk\u00e4nnande av IDE-ans\u00f6kan f\u00f6r DELIVER-studien med Liver Assist<br \/>\u2022 FDA-godk\u00e4nnande f\u00f6r fortsatt anv\u00e4ndning av XVIVOs hj\u00e4rtteknologi genom PRESERVE CAP-studien<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-fb9cf3b124f9\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r ytterligare information, v\u00e4nligen kontakta:<\/strong><\/p>\n<hr \/>\n<p>Christoffer Rosenblad, VD, +46 73 519 21 59, e-post: christoffer.rosenblad@xvivogroup.com<br \/>Kristoffer\u00a0Nordstr\u00f6m,\u00a0CFO, +46 73 519 21 64, e-post:\u00a0kristoffer.nordstrom@xvivogroup.com<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-a7a29a757a77\">\n<p><strong class=\"mfn-heading-1\">Telefonkonferens<\/strong><\/p>\n<hr \/>\n<p>Christoffer Rosenblad, VD och Kristoffer Nordstr\u00f6m, CFO, presenterar rapporten vid en telefonkonferens idag klockan 14:00. F\u00f6r anm\u00e4lan till telefonkonferensen, se tidigare pressmeddelande: https:\/\/www.xvivogroup.com\/us\/pressreleases\/telefonkonferens-avseende-delarsrapport-januari-mars-2025\/<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-da5f5ee9f867\">\n<p><strong class=\"mfn-heading-1\">Om oss<\/strong><\/p>\n<hr \/>\n<p>XVIVO grundades 1998 och \u00e4r ett medicintekniskt f\u00f6retag dedikerat till att f\u00f6rl\u00e4nga livet f\u00f6r donerade organ s\u00e5 att transplantationsteam runt om i v\u00e4rlden kan r\u00e4dda fler liv. V\u00e5ra l\u00f6sningar g\u00f6r det m\u00f6jligt f\u00f6r ledande kliniker och forskare att t\u00e4nja p\u00e5 gr\u00e4nserna f\u00f6r transplantationsmedicin.\u00a0XVIVO har sitt huvudkontor i G\u00f6teborg och har kontor och forskningsanl\u00e4ggningar p\u00e5 tv\u00e5 kontinenter. Bolaget \u00e4r noterat p\u00e5 Nasdaq Stockholm\u00a0och handlas under symbolen XVIVO. Mer information finns att l\u00e4sa p\u00e5 hemsidan www.xvivogroup.com\/us<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som XVIVO Perfusion AB \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2025-04-24 07:30 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/6144634f-c233-475a-8531-bb6b3ca754be\/xvivo-delarsrapport-q1-2025.pdf\" rel=\"noopener\" target=\"_blank\">XVIVO Del\u00e5rsrapport Q1 2025<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>F\u00f6rsta kvartalet 2025 (Jan &#8211; Mar)\u2022 Nettooms\u00e4ttningen \u00f6kade till 218,6 MSEK (186,0), motsvarande en tillv\u00e4xt om 18 procent i SEK&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-15368","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-report","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q1","mfn-news-tag-mfn"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Del\u00e5rsrapport januari-mars 2025 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport januari-mars 2025 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"F\u00f6rsta kvartalet 2025 (Jan &#8211; Mar)\u2022 Nettooms\u00e4ttningen \u00f6kade till 218,6 MSEK (186,0), motsvarande en tillv\u00e4xt om 18 procent i SEK...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2025\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2025\\\/\",\"name\":\"Del\u00e5rsrapport januari-mars 2025 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2025-04-24T05:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/delarsrapport-januari-mars-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Del\u00e5rsrapport januari-mars 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport januari-mars 2025 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/","og_locale":"en_US","og_type":"article","og_title":"Del\u00e5rsrapport januari-mars 2025 - XVIVO","og_description":"F\u00f6rsta kvartalet 2025 (Jan &#8211; Mar)\u2022 Nettooms\u00e4ttningen \u00f6kade till 218,6 MSEK (186,0), motsvarande en tillv\u00e4xt om 18 procent i SEK...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/","name":"Del\u00e5rsrapport januari-mars 2025 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2025-04-24T05:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/delarsrapport-januari-mars-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Del\u00e5rsrapport januari-mars 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/15368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=15368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}